Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18028183 | PRIME EDITING GUIDE RNAS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | Non-Final OA | President and Fellows of Harvard College |
| 17633573 | BASE EDITORS WITH DIVERSIFIED TARGETING SCOPE | Final Rejection | President and Fellows of Harvard College |
| 17604128 | PROTEIN TRANSLATIONAL CONTROL | Final Rejection | The Regents of the University of California |
| 17493186 | METHODS FOR ASSESSING RISK USING TOTAL CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin, Inc. |
| 18000834 | NOVEL TYPE I-C CRISPR-CAS SYSTEM FROM CLOSTRIDIA | Non-Final OA | NORTH CAROLINA STATE UNIVERSITY |
| 18301732 | GENOMIC EDITING WITH SITE-SPECIFIC RETROTRANSPOSONS | Non-Final OA | Massachusetts Institute of Technology |
| 18328381 | REGULATION OF METABOLISM AND OBESITY BY MITOCHONDRIAL MUL1 E3 UBIQUITIN LIGASE | Non-Final OA | University of Central Florida Research Foundation, Inc. |
| 18006278 | OPTIMIZED SLC13A5 GENES AND EXPRESSION CASSETTES AND THEIR USE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18273454 | ENHANCING EFFICIENCY OF TARGETED GENE KNOCKIN BY BASE EDITORS | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18253919 | PMO-BASED UTROPHIN::LET-7C MIRNA SITE BLOCKING OLIGONUCLEOTIDES (SBOS) FOR TREATING DUCHENNE MUSCULAR DYSTROPHY (DMD) | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18120030 | OLIGONUCLEOTIDES FOR APP MODULATION | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17917333 | COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION | Non-Final OA | ASTRAZENECA AB |
| 18315677 | PRE-CLINICAL MODIFIED RNA APPROACHES USED IN LARGE ANIMALS FOR MUSCLE AND VASCULAR REGENERATION | Non-Final OA | THE UAB RESEARCH FOUNDATION |
| 17997312 | MODIFIED NUCLEIC ACIDS ENCODING ASPARTOACYLASE (ASPA) AND VECTOR FOR GENE THERAPY | Non-Final OA | Pfizer Inc. |
| 18181583 | PREPARATION METHOD FOR MUTANT CELLS WITH DELETION OF TARGET GENES | Non-Final OA | ShanghaiTech University |
| 18017502 | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF | Non-Final OA | UCL Business Ltd |
| 17635298 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | Non-Final OA | LONZA SALES AG |
| 18005800 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SCN2A | Non-Final OA | Praxis Precision Medicines, Inc. |
| 18268023 | PEG LIPIDS AND LIPID NANOPARTICLES | Non-Final OA | GENEVANT SCIENCES GMBH |
| 17608590 | NOVEL LIGAND ASSAYS | Non-Final OA | InsituGen Limited |
| 17998419 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | Non-Final OA | Precision BioSciences, Inc. |
| 17997361 | ISOLATED RECOMBINANT ONCOLYTIC POXVIRUS CAPABLE OF BEING REGULATED AND CONTROLLED BY MICRORNA AND USE THEREOF | Non-Final OA | HANGZHOU CONVERD CO., LTD. |
| 17917472 | NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES | Non-Final OA | IO BIOSCIENCES, INC. |
| 17768104 | METHODS OF DETECTING AMINO ACID DEFICIENCIES | Non-Final OA | Pacific Northwest Research Institute |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy